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OPINION
Inclusion of gametocyte parameters 
in anti‑malarial drug efficacy studies: filling a 
neglected gap needed for malaria elimination
Rashad Abdul‑Ghani1,2*, Leonardo K. Basco3, John C. Beier4 and Mohammed A. K. Mahdy1,2
Abstract 
Standard anti‑malarial drug efficacy and drug resistance assessments neglect the gametocyte parameters in their pro‑
tocols. With the spread of drug resistance and the absence of clinically proven vaccines, the use of gametocytocidal 
drugs or drug combinations with transmission‑blocking activity is a high priority for malaria control and elimination. 
However, the limited repertoire of gametocytocidal drugs and induction of gametocytogenesis after treatment with 
certain anti‑malarial drugs necessitate both regular monitoring of gametocytocidal activities of anti‑malarial drugs in 
clinical use and the effectiveness of candidate gametocytocidal agents. Therefore, updating current protocols of anti‑
malarial drug efficacy is needed to reflect the effects of anti‑malarial drugs or drug combinations on gametocyte car‑
riage and gametocyte density along with asexual parasite density. Developing protocols of anti‑malarial drug efficacy 
that include gametocyte parameters related to both microscopic and submicroscopic gametocytaemias is important 
if drugs or drug combinations are to be strategically used in transmission‑blocking interventions in the context of 
malaria elimination. The present piece of opinion highlights the challenges in gametocyte detection and follow‑up 
and discuss the need for including the gametocyte parameter in anti‑malarial efficacy studies.
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Background
There are several integrated approaches for the assess-
ment of anti-malarial drug efficacy and drug resist-
ance: therapeutic efficacy in symptomatic patients with 
uncomplicated malaria, in vitro/ex vivo assays, molecular 
markers of drug resistance, and measurement of plasma 
concentration of anti-malarial drugs [1, 2]. Clinical stud-
ies are the gold standard for assessing the efficacy of anti-
malarial drugs, and their outcomes represent the primary 
data used for making malaria treatment policies by 
national and regional control programmes [3, 4]. Apart 
from the clinical assessment of therapeutic response 
to the drug or drug combinations, the parasitological 
parameters adopted in different protocols of clinical stud-
ies, including the standard World Health Organization 
(WHO) protocols, only address the decrease in parasite 
density of asexual forms [5–8]. Parasitologically, there-
fore, drug efficacy studies do not consider the drug effect 
on gametocyte carriage and density but focus on asexual 
parasite density. This is attributed to the fact that clini-
cal presentation of malaria is a direct consequence of the 
asexual erythrocytic stages and that gametocytes are not 
responsible for the clinical disease. Although these pro-
tocols are useful to measure the schizonticidal efficacy, 
they do not consider the gametocytocidal activity of 
the tested anti-malarial drug or drug combinations. The 
question remains as to why the gametocyte parameter is 
not routinely investigated during the 28–42  day follow-
up period. The gametocytocidal action and transmission-
blocking potential are not the major issues in most drug 
efficacy studies that primarily consider the schizonticidal 
action of anti-malarial drugs. Several clinical studies have 
focused on gametocytocidal action of different drugs 
[9–11], but once it is established, most researchers may 
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not feel the need to re-assess gametocytocidal efficacy of 
those drugs.
At present, 8-aminoquinolines (primaquine and 
tafenoquine) are the only gametocytocides that are highly 
effective against gametocytes of all human malaria spe-
cies. Artemisinin derivatives do not kill mature gameto-
cytes of Plasmodium falciparum, but indirectly inhibit 
gametocyte development by killing immature gameto-
cytes and rapidly killing asexual erythrocytic parasites 
before gametocytogenesis occurs [12]. Although pri-
maquine has been shown to stop transmission before 
the disappearance of gametocytes from the peripheral 
blood on microscopy, its use as a gametocytocidal drug 
is associated with some risks, such as haemolytic toxicity 
among patients with glucose-6-phosphate dehydrogenase 
deficiency which occurs at high frequencies (3–30  %) 
in some endemic countries, hindering its use on a large 
scale in elimination strategies [13–15]. In addition, alter-
native gametocytocidal drugs, such as tafenoquine, are 
still under clinical investigation. Recently, Eziefula et  al. 
[14] reported the lack of informativeness of gametocyte 
data in primaquine trials and proposed a strategic plan to 
optimize trial design for efficient interruption of malaria 
transmission. These authors also recommended the 
establishment of standard protocols to assess the efficacy 
of novel gametocytocidal agents, such as tafenoquine and 
methylene blue. This supports the present opinion piece 
to include the gametocyte parameter in standardized 
protocols of regular anti-malarial monitoring studies.
Is it necessary to include the gametocyte 
parameter in anti‑malarial drug efficacy studies?
Even if the drug is effective in clearing asexual para-
sitaemia and resolving malaria-associated signs and 
symptoms, gametocytogenesis can be initiated after the 
use of certain anti-malarial drugs, such as chloroquine 
and sulfadoxine-pyrimethamine [16]. Given that anti-
malarial drug resistance is widespread and drug-resistant 
parasites are more likely to produce large numbers of 
gametocytes, compared to drug-sensitive parasites, the 
transmissibility of gametocytes carrying drug-resistant 
alleles is enhanced [10, 17–24]. The inclusion of game-
tocyte parameters in the standard tests used to regularly 
assess anti-malarial drug efficacy in such situations would 
be of great value to deter anti-malarial drug resistance.
To attain malaria elimination, anti-malarial drugs or 
drug combinations should not only clear the asexual 
parasite stages responsible for clinical disease but also 
clear the sexual stages that maintain its transmission. 
To address the need for the strategic use of anti-malarial 
drugs in blocking malaria parasite transmission, the par-
allel inclusion of the gametocyte parameter with asexual 
parasite density should be prioritized in drug efficacy 
studies [12, 16]. Anti-malarial chemotherapy should spe-
cifically target gametocyte clearance to reduce or block 
parasite transmission and to prevent selection and spread 
of resistant strains [16, 25, 26].
It remains controversial whether the establishment in 
a clinical study that a certain anti-malarial drug has a 
gametocytocidal action is enough, ignoring the assess-
ment of such action in subsequent efficacy studies. Sev-
eral considerations suggest the necessity to regularly 
assess the gametocytocidal action of anti-malarial drugs 
in efficacy studies. First, the complexity of gametocy-
togenesis that involves the interaction of several host, 
environmental and biological factors [27, 28], including 
treatment with certain anti-malarial drugs, collectively 
leads to variability in gametocyte carriage and density. 
For instance, the gametocytocidal action of a drug in a 
certain geographical area could be different from another 
depending on certain factors such as the level of malaria 
endemicity and the immune status of exposed popula-
tion. Second, there could be a seasonal variation in the 
rate of gametocytaemia in the same area [29], which 
requires further investigation of possible variations in the 
gametocytocidal action of anti-malarial drugs intended 
to interrupt malaria transmission in that area. Third, in 
the face of increasing resistance to anti-malarial drugs 
that favour the increase in gametocyte density and/or 
prevalence [30, 31], a regular monitoring of gametocy-
tocidal activity of the drug in relation to the resistance 
situation to a drug becomes a priority to block parasite 
transmission and spread of drug resistance. A major 
stride in this respect is the ongoing analysis of P. falci-
parum gametocyte carriage after treatment with differ-
ent artemisinin-based combination therapy (ACT) from 
regions with different endemicity, which is being car-
ried out by the Gametocyte Carriage Study Group of the 
Worldwide Anti-malarial Resistance Network [32]. This 
initiative undertakes the determination of gametocyte 
density or prevalence at enrolment and during follow-up 
as an inclusion criterion. The main focus is on epidemio-
logical factors associated with gametocyte carriage and 
clearance after treatment with different ACT across dif-
ferent countries. Accordingly, it will likely contribute to 
devising standardized protocols for the assessment of 
anti-malarial drug and drug combination efficacy that 
include the effects of different drug regimens on gameto-
cyte carriage rate and duration within regular activities of 
national and regional malaria control programmes.
Challenges and prospects in gametocyte detection 
and follow‑up
One of the major challenges is the gap between the 
detectable gametocytes and infective level of game-
tocytaemia. Although the microscopic detection of 
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Plasmodium gametocytes may be as low as 10–20 game-
tocytes/µl [33], sub-microscopic gametocyte densities 
can infect vector mosquitoes [34–36]. In the standard 
WHO protocol for therapeutic efficacy, the microsco-
pist reports whether gametocytes were observed while 
performing routine counts of asexual parasites, which 
is easier for the characteristic banana-shaped P. falci-
parum gametocytes compared to those of other species 
(which are rounded bodies that may be mistaken for 
mature asexual trophozoites). Sensitivity of microscopy 
is not enough for the detection of a low gametocytae-
mia [37]. In addition to being unrelated to clinical signs 
and symptoms of the disease, the longer time required to 
detect and count gametocytes is one of the major reasons 
to ignore routine counting of gametocytes during anti-
malarial efficacy trials. Two types of counts are suggested 
to be performed on thick blood smears: a first count of 
asexual parasites against 200 white blood cells (WBCs) 
according to standard WHO protocols and a second 
count for gametocytes against at least 500 WBCs as pre-
viously reported [38, 39]. However, counting gametocytes 
against 500 WBCs should be revised and optimized as 
this comes down to about 20–30 high power fields, which 
seems to be far too little.
The question remains as for how long the presence of 
gametocytes should be monitored after treatment, i.e., 
the duration of gametocyte carriage. The follow-up inter-
vals for the assessment of gametocyte carriage and game-
tocyte density should be different from those of asexual 
parasites because of the slower development of P. falci-
parum gametocytes (up to 10 days) compared to that of 
asexual erythrocytic stages [40]. In general, gametocytae-
mia is usually measured on a weekly basis starting on the 
day of treatment until the end of the fourth week of treat-
ment when it peaks and then starts to decline [22]. There-
fore, there is a need to establish the best chronological 
follow-up pattern that would even extend beyond that 
for asexual parasitaemia due to the relative persistence 
of gametocytes in the blood. The period of follow-up will 
be different, where asexual parasites should be counted 
according to standard WHO protocols (i.e., 28–42 days) 
whereas gametocytes should be screened at weekly inter-
vals for a longer period, at least 42 days. However, opti-
mization of the follow-up period for gametocytes is yet to 
be explored. It is noteworthy that an innovative magnetic 
fractionation approach for on-site counting of gameto-
cytes in field studies has been introduced as an alterna-
tive to light microscopy with a sensitivity comparable to 
that of reverse transcriptase polymerase chain reaction 
(RT-PCR) [39].
In case of sub-microscopic infections where counts 
could not be performed, gametocytes can be detected and 
their load can be quantified using molecular techniques. 
The adoption of specific molecular approaches, such as 
real-time RT-PCR for gametocytes, facilitates their detec-
tion and quantitation [41–43]. In line with the efforts 
devoted to eliminating malaria transmission, molecular 
detection of Plasmodium gametocytes could help in two 
directions: epidemiologically for uncovering the sub-
microscopic human reservoir and clinically for monitor-
ing gametocytocidal activity of transmission-blocking 
anti-malarial drugs. This is particularly important since 
masked or invisible infectious reservoir in endemic areas 
is much greater than that revealed by microscopy and it 
maintains malaria transmission [37, 44–47].
Attempts to discover innovative, rapid techniques for 
the detection of gametocytes could help overcome tech-
nical difficulties encountered in determining gametocy-
taemia by microscopy. This becomes feasible in the field 
with the introduction of easy, reliable filter-paper blood 
collection as well as loop-mediated isothermal amplifica-
tion (LAMP) technique for the detection of low-density 
parasite gametocytes [48–51]. The development of a 
reverse transcriptase-LAMP for the detection of P. falci-
parum gametocytes in clinical specimens [49] may pave 
the way for the innovation of rapid, simple molecular 
tests for detection and quantitation of sub-microscopic 
gametocytes for discriminating between blocking and 
non-blocking agents and monitoring possible changes 
in the activity of available gametocytocidal drugs. Other 
approaches to explore include concentration of gameto-
cytes prior to amplification by PCR, PCR using a high vol-
ume (i.e., 5–15 ml) of venous blood, quantitative nucleic 
acid sequence based amplification, PCR with intron-
spanning primers, and alternative molecular targets with 
multiple copies [52–55]. The search for methodologies 
to overcome difficulties in detecting gametocytaemia in 
low transmission settings should be given attention. For 
instance, some authors have reported the utility of exam-
ining pooled samples in malaria diagnosis from differ-
ent endemic settings [56–60]. This approach needs to be 
investigated with regard to detecting low-density game-
tocytaemia in clinical trials determining the gametocy-
tocidal activity of anti-malarial drugs. However, further 
research, optimization and interpretation strategies are 
required to test the efficiency of sample pooling in game-
tocyte detection in different epidemiological settings. 
On a broader scale, more attention should be given to 
explore the utility of molecular tools as a complementary 
approach to provide data on gametocyte load retrospec-
tively in relation to studies on therapeutic efficacy.
One of the best available measures to address the poten-
tial of malaria parasite transmission after treatment with 
anti-malarial drugs may be to adopt the area-under-the-
curve (AUC) of gametocyte levels combining the duration 
of gametocyte carriage and their density [22], although 
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it may underestimate relationships between doses and 
therapeutic responses to gametocytocidal drugs in trans-
mission-blocking studies [61]. For instance, the Four Arte-
misinin-Based Combinations Study Group used the AUC 
to assess gametocyte prevalence during follow-up of four 
artemisinin-based combinations in the treatment of uncom-
plicated malaria in seven African countries [62]. Despite 
the feasibility and applicability of the AUC in observational 
studies and clinical trials [22], its incorporation in measur-
ing the gametocytocidal efficacy of anti-malarial drugs in 
routine anti-malarial drug efficacy studies is yet to be inves-
tigated. Therefore, follow-up protocols, monitoring both 
parasite density and gametocyte microscopic count or sub-
microscopic load, have to be developed and evaluated for 
assessing anti-malarial drug or drug combination efficacies 
in different epidemiologic settings. In addition, the renewed 
interest in the assessment of the transmission-blocking 
activity of drugs and vaccines raises hope regarding the 
search for the best measures to evaluate their effects [61].
Apart from the determination of gametocyte carriage 
and gametocyte density after anti-malarial treatment, 
another challenge is infectivity measurement of gameto-
cytes to vector mosquitoes. Transmissibility of infection 
from humans to mosquitoes is affected by a variety of host, 
parasite and vector factors [37]. Although it goes beyond 
the scope of the present opinion piece, it is noteworthy 
that there is no linear relationship between gametocyte 
density and infection rates of vector mosquitoes [63], and 
low-level or even sub-microscopic gametocytaemias can 
infect vector mosquitoes in certain settings [34–37]. In 
an attempt to devise tools to assess the transmissibility 
of infection, Joice et  al. [64] recently developed and vali-
dated a method for the estimation of the relative quantities 
of asexual and sexual stages of P. falciparum that can be 
applied to infer maturity of gametocytes both in laboratory 
and in the field studies of malaria transmission.
Malaria elimination through drug-mediated transmis-
sion blocking of mature, viable male and female gameto-
cytes to mosquitoes is a novel approach [65–67], which 
necessitates the adoption of appropriate strategies for 
assessing the transmission-blocking potential of the cur-
rent and next generation of anti-malarials. The block-
ing potential of novel gametocytocidal agents can be 
determined by assessing the functional viability of drug-
treated mature male and female gametocytes  using P. 
falciparum dual gamete formation assay [68, 69]. Novel, 
high-throughput assays for assessing the functional via-
bility of transmission stages of malaria parasites have 
recently been developed and validated to enable the iden-
tification of potent gametocytocidal agents that have a 
sterilizing effect on gametocytes, in particular on the 
more drug-sensitive mature male gametocytes [68, 70, 
71]. Novel tools and approaches for the assessment of 
gametocyte parameters in drug efficacy studies will be 
indispensable as an increasing number of countries and 
sub-regions aim to eliminate malaria in the coming years.
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